Cracking the Human Cytomegalovirus Code: Trinary Challenges of Latency, Immune Evasion, and Correlates of Protection

Somayeh Mami[1], Sajjad Shekarchian[2], Mohammad Javad Mousavi[3,4], and Mohammad Hossein Nicknam[1,5]

[1] Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
[2] Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
[3] Department of Hematology, School of Para-Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
[4] Clinical Research Development Center, The Persian Gulf Martyrs Hospital, Bushehr University
of Medical Sciences, Bushehr, Iran
[5] Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Human cytomegalovirus (HCMV) poses a significant challenge to vaccine development due to its complex biology characterized by latency, immune evasion strategies, and undefined correlates of protection (CoPs). HCMV latency allows the virus to evade immune surveillance by remaining in a quiescent state in host cells, with the risk of reactivation triggered by immune damage or cell differentiation. In addition, HCMV employs an arsenal of immune evasion strategies, including modulating MHC expression, inhibiting natural killer (NK) cell activity, and subverting antibody-mediated responses, so these mechanisms further complicate vaccine design. Despite these obstacles, advances in basic research in immunology and vaccine technologies offer new opportunities. Strategies such as targeting latency-associated mechanisms, using memory inflation of CMV-specific T cells to induce long-term tissue-resident immunity, and developing immunogens that antagonize viral immunoevasins are promising approaches. New platforms, including mRNA and vector-based vaccines, show the potential to elicit robust humoral and cellular responses against key viral antigens such as glycoprotein B, pentamer complex, and pp65. In addition, adjuvants that restore impaired NK and T cell function could improve vaccine effectiveness. This review examines the molecular and immunological barriers to HCMV vaccine development and highlights innovative approaches to address these challenges. By addressing the complexities of latency, immune evasion, and CoPs, we propose a roadmap for developing a multimodal vaccine that can provide effective and durable protection against HCMV infections.

Keywords: Human cytomegalovirus; Immune evasion; Latency; Memory inflation; mRNA vaccines; Vaccine development

Corresponding Authors: Mohammad Hossein Nicknam, MD, PhD;
Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Tel: (+98 21) 611 3207, Fax: (+98 21) 642 2337, Email: mhnicknam@sina.tums.ac.ir

Mohammad Javad Mousavi, PhD;
Department of Hematology, School of Para-Medicine, Bushehr University of Medical Sciences, Bushehr, Iran. Tel: (+98 912) 469 1226, Fax: (+98 75) 187 59577, Email: M.j.mousavi@bpums.ac.ir

INTRODUCTION

Cytomegalovirus (CMV) is an enveloped DNA virus that belongs to the herpesvirus family. After the initial infection, the virus remains latent in body tissues for life.[1] In healthy individuals, heterophile-negative infectious mononucleosis is the most common complication of CMV infection in most populations.[2] However, organ transplant recipients, acquired immunodeficiency syndrome patients, premature infants, and patients with various malignancies sometimes experience viral reactivation or reinfection with a different strain of CMV. This infection is called a recurrent infection.[3] Women who become infected with CMV during pregnancy can transmit the infection to their fetus, resulting in permanent disabilities such as hearing loss, vision loss, and intellectual disability in the child.[4] CMV infection is found to be common in organ transplant recipients and has the potential to result in severe symptoms such as pneumonia, hepatitis, chorioretinitis, and even death. In addition, although antiviral therapies (ganciclovir and foscarnet) are available for the treatment of CMV infections in immunocompromised patients, there is a need for new treatment options with fewer side effects.[5,6]

Developing an effective vaccine against CMV could be very effective in combating this virus.[7] In the 1960s and 1970s, studies of the CMV virus began, and in these years, CMV was recognized as an important cause of infections and congenital diseases.[8] Development of the CMV vaccine began in the 1970s with attenuated strains, and in the 1980s, one of its strains was shown to be safe and effective in kidney transplant patients.[9] Many vaccines have been tested since 2000. For example, targeting specific proteins such as glycoprotein B (gB) has been considered. According to studies, antibodies against gB may be a good option for a CMV vaccine since it plays a role in the virus' fusion with the host cell surface. This is because antibodies against gB may neutralize CMV infection in fibroblast cells.[10,11] Studies have shown that the gB vaccine, when administered with the MF59 adjuvant, sparks antibodies against the antigen domain that controls cell-to-cell spread.[11] Further studies have shown that pp65 in CMV vaccines is a main point of attack for cellular immune responses.[12] The subsequent discovery of the pentameric protein complex (PC) that produces most neutralizing antibodies led to efforts to incorporate this complex into vaccines. Studies have shown that neutralizing antibodies specific to PC are much more effective than antibodies against gB in neutralizing infections in epithelial cells, endothelial cells, and monocytes.[13] Furthermore, the presence of maternal antibodies to PC early in pregnancy has been associated with a reduced risk of HCMV transmission to the fetus.[14]

Today, vaccines against CMV have been developed with different platforms, including live attenuated, recombinant viral proteins, dense bodies, viral-vector vaccine, subunits, or synthetic peptide epitopes.

These vaccines have been extensively evaluated using various animal models and have shown promising immunogenicity and protective efficacy.[15-20] Some vaccines have also entered clinical trials.[21-33] Among the most recent vaccines against CMV are with new technologies, such as the mRNA vaccine, which uses the gB-PP65-PC antigens in its structure and has shown promising results.[34] Despite all the studies that have been conducted, the development of a suitable vaccine against CMV is considered problematic work due to several reasons, such as the complex immunobiology of the virus, its ability to cause latent infection[35] and the ability to evade the immune system in various ways, and the lack of a clear correlate of protection (CoP) for HCMV.[36] This review examines some of the issues that give rise to challenges in developing a vaccine against HCMV.

CMV Latency

A significant hurdle to developing a successful vaccine is CMV latency.[37,38] During latency, the CMV genome persists in certain cells without producing new viruses.[37,39] As a result, the immune system stops recognizing the virus and it improves resistance to antiviral medications that target viruses that are actively replicating.[38] This phenomenon causes a challenge for vaccine development because the primary target of vaccines is to induce recognition and elimination of actively replicating viruses by the immune system. In individuals with compromised immune systems or transplant recipients, latent viruses can reactivate and cause medical conditions.[38,40] Given that current antiviral therapies only put a damper on the replication of active CMV and not latent viruses, it raises significant red flags.[38,41] The effectiveness of a CMV vaccine depends on its ability to target latently infected cells and end their reactivation in addition to preventing the

occurrence of primary infection.[38] A deeper insight into the mechanisms underlying CMV latency emergence, viral reactivation triggers, and immune responses to latent infection is necessary to bring about this herculean challenge.

The Mechanisms of CMV Latency

CMV latency is described as a complex process involving viral and host factors that suppress viral replication and let go of the viral genome in a quiescent state. This gives the opportunity for the virus to remain throughout the host's lifetime without being recognized and eliminated by the immune system. A hallmark of latency is the restricted expression of viral genes essential for active replication.[37] During latency, key viral genes that drive replication are turned off, particularly the major immediate-early (*MIE*) gene locus, which is crucial for viral activation.[42] To control its expression during latency, the MIEP region (MIE enhancer/promoter) is specifically regulated in a variety of ways (Figure 1A).[42] Chromatin remodeling creates a tightly packed structure around the *MIE* gene, preventing the virus from becoming active. For example, MIEP-associated histones at H3K9 and H3K27 become trimethylated (me3) during latency.[43,44] These changes are related to gene silencing and produce a repressive environment. Cellular repressor proteins such as heterochromatin protein 1 (HP1), epidermal growth factor receptor-related factor (ERF), Ying Yang 1 (YY1), and KRAB-associated protein 1 (KAP1), also interact with MIEP or adjacent regions and on top of that, contribute to transcriptional repression.[43-48]

The virus also gives rise to factors that play a role in maintaining latency. For example, viral long non-coding RNA 4.9 has been shown to become associated with MIEP and recruit the polycomb repressive complex 2 (PRC2) repressor complex.[49] Moreover, HCMV encodes microRNAs that target and bring under control host cell factors involved in various processes, including cell signaling pathways.[50,51] Some HCMV microRNAs directly coordinate viral transcripts to dampen lytic gene expression.[50] HCMV can manipulate cell signaling pathways to form a favorable environment for latency. Viral proteins, including pp71, a viral transactivator critical for lytic infection, are taken out of the nucleus of latently infected cells, preventing initiation of lytic gene expression.[52,53] Some studies also give evidence of the role of cell signaling in suppressing *MIE* gene expression.[54-56] However, the specific signaling processes and pathways involved are not well understood. Cell differentiation affects HCMV latency as a dynamic process. Though their precise function in CMV pathogenesis is not well understood, other cell types have the potential to harbor latent viruses, even though latency is mainly studied in hematopoietic progenitor cells (HPCs), including CD34+ cells and CD14+ monocytes.[57-60] The differentiation of HPCs into mature myeloid cells, including dendritic cells and macrophages, has a strong correlation with the shift from quiescence to reactivation. This differentiation process can spark changes in cell signaling and chromatin structure that promote virus reactivation.[43,44,58,61]

According to most investigations, CMV latency is a sophisticated tactic the virus has developed to stay in the host. The virus takes a multifaceted approach that includes limiting viral gene expression, manipulating host cell signaling, and exploiting cellular differentiation processes to create an environment that favors latency. This complexity poses significant challenges for developing vaccines and therapies to eliminate the latent CMV reservoir.

Factors Triggering CMV Reactivation

Several elements, such as cell differentiation, inflammatory signals, and cell signaling pathways, play a role in the reactivation of latent CMV.[37,50,62] These elements provide the opportunity for the virus to re-enter the lytic replication cycle by upsetting the fragile state that maintains viral latency. Primary in CMV reactivation is the differentiation of latently infected HPCs, particularly CD34+ cells and CD14+ monocytes, into mature myeloid cells like dendritic cells and macrophages.[44,59,60,63,64] Alterations in the cellular environment, such as modifications to signaling pathways, chromatin structure, and gene expression, arise during the transition from a progenitor to a differentiated state.[42] These modifications are likely to make the environment more conducive to the virus's reactivation. For instance, repressors can be eliminated, and transcriptional activators can interact more efficiently when differentiation-dependent chromatin remodeling occurs around the *MIE* locus, particularly in the MIEP region.[65-67] Furthermore, signaling pathways and differentiation-specific transcription factors (dsTFs) have the potential to be triggered, which would facilitate the process of the start of viral gene expression.[68,69]

CMV reactivation is strongly tied to immune activation and inflammatory signals.[70] Interferon

gamma (IFN-γ), tumor necrosis factor (TNF), and interleukin 6 (IL-6) are examples of proinflammatory cytokines that have a positive effect on myeloid cell maturation and have a hand in the CMV reactivation process.[71-73] These cytokines, often secreted in response to stress, infection, or tissue damage, can activate signaling pathways that disrupt latency and promote viral gene expression.[40] They can, for instance, trigger the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, a crucial modulator of immunological responses and inflammation, which can attach to MIEP directly and initiate its activation.[70] It is crucial to remember that immunosuppression can indirectly aid in CMV reactivation, despite its apparent paradox. Reduced NK immune surveillance in immunocompromised people can result in inflammatory diseases or other opportunistic infections that can release proinflammatory cytokines and, eventually, CMV reactivation.[74-76]

Shifts in cell signaling pathways are of utmost importance for checking the ratio of reactivation to quiescence. Several factors, including cytokines, growth factors, and cellular stress, can influence these interconnected signaling pathways.[77] Mitogen-activated protein kinase (MAPK) signaling, phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) signaling, and other signaling pathways are central to CMV reactivation.[77] In certain cell types, the MAPK pathway – particularly the ERK-MAPK branch – has been found to be a critical mediator of CMV reactivation.[44,78] Stimulation of this pathway can lead to phosphorylation and activation of transcription factors such as cAMP response element-binding protein (CREB), which binds to MIEP and initiates the expression of viral genes.[79] It is important to remember that MAPK signaling appears to play a cell type-specific role in reactivation and that blocking this pathway may even promote reactivation in various situations.[44,80] Another important signaling cascade tied to reactivation is PI3K/Akt/mTOR signaling. For example, growth factors, such as epidermal growth factor (EGF), are prone to spark this pathway, increasing cell survival and proliferation, and potentially resulting in reactivation.[81-83] Mechanistically, KRAB-associated protein 1 (KAP1), a cellular suppressor protein that binds to MIEP, can also be phosphorylated by mTOR activation.[84] This phosphorylation event impairs the ability of KAP1 to repress and could be a factor in its reactivation.[85,86] The function of PI3K/Akt/mTOR

signaling in reactivation is likely to be complex and context-dependent, similar to the MAPK signaling pathway. Although their precise functions are unclear, some additional signaling pathways have been suggested to play a role in CMV reactivation. These contain stress-activated kinase pathways, G protein-coupled receptor signaling, and the cAMP/PKA pathway (Figure 1C).[79,87-90] Further investigation is required to fully understand how these different signaling pathways interact and how they contribute to CMV reactivation.

It is possible that other factors, such as allogeneic stimulation, stress, and viral factors, contribute to CMV reactivation.[37,91-93] Contact of latently infected cells with allogeneic cells, for example, during a transplant, tends to result in CMV reactivation.[91] The mechanism behind this phenomenon is not yet fully understood, but it is probably based on the activation of immune reactions and inflammatory signals.[91] Furthermore, a variety of stress factors, such as hypoxia, nutrient deficiency, and DNA damage, can induce CMV reactivation.[94-97] These stressors frequently initiate cellular signaling routes that disturb latency and result in viral gene expression. Specific viral proteins have demonstrated an ability to aid in reactivating. An example is the viral protein US28, which is similar to a chemokine receptor and has been shown to influence cell signaling pathways and play a role in reactivation. However, how it works exactly is still a topic of debate (Figure 1B).[37]

It is crucial to understand that these factors often interact synergistically and that multiple signals may be required to overcome the barriers to maintaining viral latency. The specific combination of factors that trigger reactivation can vary depending on the type of host cell, the immune status of the individual, and the CMV strain. Further investigation is necessary to unravel the intricate relationship between these factors.

Figure 1. Key mechanisms of cytomegalovirus (CMV) latency and reactivation in CD34$^+$ hematopoietic progenitor cells (HPCs) and monocytes: The figure illustrates the intricate molecular and cellular processes underlying CMV latency establishment, maintenance, and eventual reactivation within CD34$^+$ hematopoietic progenitor cells (HPCs) and monocytes. There are three critical steps: A. Establishment of Latency: Upon CMV infection, the viral genome enters the host nucleus where latency is initiated. Long noncoding RNAs and microRNAs encoded by CMV target host signaling pathways, resulting in the silencing of the major immediate-early promoter (MIEP) through chromatin remodeling. This involves histone modifications such as H3K9 trimethylation and H3K27 trimethylation, preventing transcription of lytic genes and establishing a latent state. B. Maintenance of Latency: During latency, host-derived repression proteins such as heterochromatin protein 1 (HP1) and KRAB-associated protein 1 (KAP1) bind to the MIEP, further stabilizing its silenced state. The viral-encoded US28 protein actively attenuates host signaling pathways, reinforcing latency by preventing immune recognition and minimizing cellular activation. C. Reactivation of CMV: Reactivation is triggered by external stimuli, including inflammatory cytokines (e.g., tumor necrosis factor [TNF], interleukin 6 [IL-6]) and cellular differentiation into macrophages or dendritic cells. These signals activate the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, which disrupt chromatin remodeling and reactivate the MIEP. This allows for the production of viral proteins and eventual viral replication in differentiated cells.

The Immune System and Latent CMV

CMV infection comes to pass in three stages (i.e., lytic, persistent, and latent), with each stage exerting an influence on the immune response uniquely. CMV latency, hand in hand with the viral reactivation, gives rise to three specific immune responses against latent CMV. These responses comprise CMV-specific T cell responses, memory inflation, and natural killer-like CD8 T cells.[98] Following CMV infection, CMV-specific T cells undergo a phenotypic transition from effector cells to memory cells, encompassing effector memory (TEM), central memory (TCM), and tissue-resident memory (TRM) subsets.[99] Within TCM cells, a limited group of inflationary memory CD8[+] T cells, found mainly in lymph nodes with small numbers in the spleen, are the most important TCM cell subset in response to latent CMV infection.[98]

Essential subsets of TEM cells that elicit a significant functional response against latent CMV infection comprise CD8 effector memory cells re-expressing CD45RA (TEMRA), CD4 TEMRA, and Cytotoxic CD4 T cells (CTL). TEMRA CD8 cells exhibit lower proliferation compared to effector cells, but they have the capacity to generate significant amounts of IFN-γ. Depending on the CD57 expression, these cells are subdivided into two types: CD57[+] TEMRA, which are in the terminal expansion phase of the immune response, and CD57[-] TEMRA, which have a higher proliferation capacity and are more flexible in differentiation.[99,100] CD4 TEMRA cell subsets are fewer in number than CD8 TEMRA cells. These cells comprise under 10% of all CMV-specific IFN-γ[+] CD4 T cells and provide a clue to CD57, viewed as a marker of polyfunctionality, particularly in CMV-positive individuals.[101-103] A subset of the T cells (CD57[+]CD27[-]CD28[-]CD244[+]) is cytotoxic and shows TCR oligoclonality. Studies have shown specific stages of CD4 CTL differentiation marked by CCL3, CCL4, and CCL5 proteins and supported by common TCR complexes.[104,105] CD4 CTLs are found more frequently in specific organs (like the spleen and liver) and are not present in others, including salivary glands (SGs).[106,107] TRM cells generate tissue-specific responses in tissues affected by CMV infection in both mice and humans. These cells are categorized into two subtypes: CD8 TRM cells, characterized by CD103 and CD69 markers, and CD4 TRM cells, identified by CD11a and CD69 markers.[108-110]

Memory inflation, a distinctive feature of CMV-specific CD8 T cells, is characterized by continued expansion during the latent phase of CMV infection, rather than the typical cycle of expansion and contraction. These cells achieve sustained levels in different tissues and continue their functional and often memory-like phenotype over time.[111] Protease processing, antigen avidity for MHC and TCR, Tcf1[+] cells, and the reactivation of latent infection in lymphatic endothelial cells are some contributing elements that play a role in memory inflation. Sporadic reactivation of CMV in latently infected lymphatic endothelial cells sparks CMV-specific T cells, leading to their expansion.[112,113] A subset of Tcf1[+] cells promotes the maintenance of the inflationary T cell pool in response to cytokines such as IL-12 and type I interferons.[114] Only certain peptides that are processed by the constitutive proteasome in infected cells (not the immunoproteasome) are permitted to give rise to inflammatory responses.[115] A significant factor in raising memory inflation is the location and avidity binding of peptide antigens to MHC molecules.[116] CMV-specific inflationary T cells are characterized by distinctive features such as phenotypic markers and tissue distribution that facilitate their identification. These cells express markers of effector memory (such as CD45RA for TEMRA cells), markers of T cell maturation, and sometimes conventional markers of natural killer (NK) cells. High frequencies of inflammatory cells are found in the spleen, blood circulation, and various peripheral tissues.[111] Memory inflation plays a protective role by enabling CMV-specific T cells to incessantly "scan" the body for reactivation of the virus. This surveillance prevents viral relapse and contributes to long-term control of CMV in infected individuals. The number of these inflationary T cells directly correlates with their ability to protect against CMV reactivation.[98] Understanding memory inflation is valuable for CMV vaccine strategies because vaccines can be designed to induce long-lasting, inflationary T cells that provide robust and sustained immune surveillance against CMV. On the other hand, it is possible that mimicking the inflationary response in vaccine design will give rise to vaccines that have wide tissue distribution and a strong cytotoxic response against CMV-infected cells.

CMV-specific T cells upregulate NK cell markers, including CD57, KIRs, LIRs, and CX3CR1, associated

with NK cell molecules that distinguish these cells from conventional T cells. These cells produce high levels of inflammatory cytokines and have the potential to become degranulated in CMV-positive individuals, as shown by the CD107a marker on the plasma membrane.[117] NKG2C, in combination with other NK cell markers such as CD56 and KIR, are upregulated in CD8 T cells during the course of HCMV infection. These cells are oligoclonal and do not express PD-1 despite the fact that they are stimulated over a long duration. These NKG2C[+] CD8 T cells demonstrate robust effector functions against HCMV-infected fibroblasts through the interaction of NKG2C and TCR. Transcriptional analysis shows that BCL11B, a transcription factor in these NKG2C[+] CD8 T cells, plays a role in their developmental fate. Deletion of BCL11B in normal CD8 T cells gives rise to an innate-like population (CD56[+]CD94[+]DAP12[+]NKG2C[+]CD45RA[+]CCR7[−]PD[−/low]) capable of targeting HLA-E[+] cells.[118] Terminally differentiated CMV-specific CD8 T cells usually express high levels of NKG2C.[119] NKG2C specifically recognizes CMV UL40 protein peptides presented in the HLA-E context and promotes adaptive NK cell expansion. CD94/NKG2C is also involved in alternative activation pathways for CD8 T cells.[120,121]

The intricate molecular details surrounding HCMV latency provide important foundations for developing innovative vaccines. These findings may transform vaccine design by addressing challenges specific to the life cycle of HCMV and its interactions with the host immune system. Latency represents a significant hurdle in vaccine development because latent HCMV is invisible to immune surveillance.[76] Innovative vaccine strategies could focus on disrupting latency-maintaining mechanisms, such as chromatin remodeling at the MIE promoter, or on viral factors, such as long noncoding RNAs and microRNAs that regulate latency. Vaccines could aim to activate latent viruses in a controlled manner to expose them to immune-mediated clearance.[122-124] The expansion of CMV-specific T cells with unique properties, such as inflationary memory CD8[+] T cells, has the potential to provide a natural model for vaccine development. Vaccines could aim to mimic this memory inflation phenomenon to generate long-lived, tissue-resident T cells capable of monitoring latent reservoirs and controlling reactivation. HCMV-specific T cells expressing NK markers (e.g., NKG2C, CD57) exhibit potent antiviral effects.[125] Vaccines that

promote the development of such T/NK hybrid populations could represent an effective tool to combat HCMV. Incorporation of adjuvants that stimulate signaling pathways involved in maintaining or reactivating latency could improve vaccine efficacy. For example, targeting KAP1/TRIM28 or other chromatin-modulating factors could promote immune responses against latent cells.[48,126,127]

Immune Evasion

A significant portion of HCMV's genetic elements is evolved to evade host defenses (Table 1). Of the approximately 170 open reading frames, most genes (70%) are dispensable for viral replication in vitro,[128] and many have been suggested to modulate host immunity.[129-131] All major viral gene classes, including immediate-early, early, late, and latency-associated proteins, as well as noncoding RNAs, are part of this evasion strategy. The CMV-encoded immunoevasin families include the UL18 family, the US region gene cluster, the RL11 family, and the US12 family.[132]The UL18 ORF, an MHC class I homolog, encodes a glycoprotein that comes together to form complexes with β2-microglobulin and peptides. This glycoprotein is exposed to post-translational modifications that lead to the expression of a mature form, gpUL18, in the latter stages of HCMV infection and appears to play a role in modulating NK responses.[133] The US region gene cluster encompasses 2 gene families, US2 and US6, which are involved in regulating MHC-I cell surface expression.[134,135] The RL11 family embraces several members (e.g., RL5A, RL6, RL11-13, UL1,4-11), some of which, such as RL11-13, prevent the activation of the Fc receptor (FcR) by binding to the Fc region of the IgG molecule.[129,136] The US12 family consists of a tandem array of US12-21, which are engaged in regulating the expression of NK ligands, adhesion molecules, and cytokine receptors.[131,137] HCMV resorts to a multifaceted strategy to evade host immunity. These strategies involve modulating the infected cell's antiviral mechanisms, the innate immune response, and the adaptive immune response.

Table 1. Summary of key immunoevasins of human cytomegalovirus

Immunoevasin	Target	Mechanism of Action	Reference
UL18	NK cells (LIR1 receptor)	Mimics MHC-I to bind LIR1 on NK cells, reducing cytotoxicity.	[134]
US2, US6	MHC-I molecules	Downregulate MHC-I expression by targeting heavy chains for proteasomal degradation (US2) and blocking peptide transport (US6).	[135,136]
RL11	IgG molecules	Prevents Fc receptor activation by binding to the Fc region of IgG.	[130,137]
US12 Family	NK ligands, adhesion molecules	Modulates ligand expression, reducing NK cell recognition and adhesion molecule signaling.	[132,138]
LUNA, IE72, pp77	Intracellular immune sensors (e.g., cGAS-STING pathway)	Modulates intracellular antiviral signaling pathways and disrupts nuclear domains to facilitate immune evasion.	[138,143]
vMIA (pUL37x1)	Apoptosis pathways	Inhibits mitochondrial apoptosis by binding to ANT and preventing membrane permeability changes.	[152]
UL40	HLA-E molecules	Mimics MHC signal peptides, stabilizing HLA-E to inhibit NK cells through their inhibitory receptors.	[173,176]
UL142, UL16	NKG2D ligands (e.g., MIC-A, ULBP1)	Induces degradation or retention of NKG2D ligands in Golgi to escape NK cell detection.	[177,180]
gp68, gp34 (RL11 family)	Fc region of IgG	Prevents antibody-mediated NK cell activation by masking IgG Fc regions.	[189,193]
pp65	DNA sensors like cGAS	Inactivates cGAS to reduce interferon production.	[147]
UL111A (cmvIL-10)	Immune suppressor pathways	Upregulates host IL-10, enhancing immunosuppressive effects.	[223]
US3	Peptide loading complex (TAP)	Inhibits TAP and tapasin, preventing MHC-I peptide loading and expression.	[219,220]
UL141	TRAIL death receptors	Binds and retains TRAIL death receptors intracellularly, preventing TRAIL-mediated NK killing.	[195]

ANT: adenine nucleotide translocator; cGAS: cyclic GMP-AMP synthase; Fc: fragment crystallizable region; HLA-E: human leukocyte antigen E; IL-10: interleukin 10; IgG: immunoglobulin G; LIR1: leukocyte immunoglobulin-like receptor 1; MHC-I: major histocompatibility complex class I; MICA: MHC class I chain-related protein A; NK: natural killer cells; NKG2D: natural killer group 2D; UL18: human cytomegalovirus (HCMV) immune evasion protein; ULBP1: ULBP1 protein; US2: unknown signal protein 2; US6: unknown signal protein 6; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand.

Modulation of the Antiviral Mechanism of Infected Cells

When HCMV infects the host cell, it generates factors that either put the brakes on the antiviral responses within the infected cell or curb the production of cytokines such as IFN-I from the infected cell to spark an antiviral response. One of HCMV's strategies to modulate the immune response is to restrain intracellular sensors involved in virus recognition. These sensors include the DN10:Sp100:hDaXX complex, which hinders the process of the viral genome integrating into the host by disrupting nuclear domains, the factors GAL9 and SPOC1 involved in the antiviral response, ZBP1, a sensor of viral transcribed RNA, and the cGAS-STING pathway and IFI16, which are involved in the recognition of viral DNA.[137-142] Through the production of factors such as LUNA, IE72, and pp77/UL35, HCMV results in host epigenetic regulation that can impact viral replication, latency, and reactivation.[143-145] Another strategy of HCMV to modulate the antiviral mechanisms is to target signaling pathways such as NF-κB, IRF-3, and signaling pathways stimulated in response to IFN-I. By expressing factors such as PP65, UL23, UL44, and LncRNA1.2, this virus can suppress these signaling pathways.[146-149] Human CMV can also neutralize the antiviral effects of IFN-I. MxB falls into the category of interferon-inducible protein with potential antiviral activity that interferes with protein translation and cell cycle initiation. pUL69 can induce initiation and prevent cell cycle progression by impairing MxB function.[150] IFN-I impacts the expression of IFN-stimulated genes (ISGs), which influence an antiviral response, by operating on the Interferon-sensitive response element (ISRE). By expressing UL23, HCMV obstructs STAT1 phosphorylation, which is necessary for IFN-I signaling, and ultimately throws a spanner in the works of the IFN-I response after infection.[149]

On top of that, the HCMV virus can prevent the clearing away of the infected cell source by suppressing programmed cell death through factors such as IE1-p72, vICA, and vMIA, ultimately leading to immune system evasion. Human cytomegalovirus (HCMV) encodes a protein called viral mitochondria-localized apoptosis inhibitor (vMIA) or pUL37x1, which acts as a potent apoptosis inhibitor. This protein, which results from the expression of the immediate-early gene UL37, accumulates mainly in the mitochondria of infected cells. There is evidence that vMIA binds to the outer mitochondrial membrane by forming a complex with the Adenine Nucleotide Translocator (ANT) and halts the progression of the apoptotic process by preventing the permeability of this membrane. This protective mechanism allows the virus to resist a variety of apoptotic stimuli, including signaling from cell death receptors, cytotoxic agents, and secondary infections with other viruses such as adenovirus.[151] Human CMV has demonstrated the unique ability to inhibit multiple necroptosis pathways. By targeting the downstream steps of RHIM signaling, particularly after RIP3-dependent phosphorylation of MLKL, this virus inhibits both the TNF-α receptor (TNFR1) and M45mutRHIM-induced necroptosis. The crucial role of viral protein E1 in suppressing TNFR1-dependent necroptosis was confirmed. Furthermore, the IE1 p72 isoform plays an important role in creating an environment resistant to necroptosis by influencing host cell response and modulating interferon activation. The IE1 mutant virus results also highlight that IE1-p72 is necessary to protect cells from TNFR1-dependent signaling and plays a key role in creating this protective environment.[152]

Modulation of Innate Immune Responses

The evasion of innate immunity by CMV is evidence of its evolutionary complexity and gives rise to challenges for the control of this virus. Efforts to address these evasion strategies are critical to address the significant health burden of CMV, particularly in high-risk populations. Human cytomegalovirus (HCMV) has developed several strategies to evade the innate immune response. Specifically, HCMV circumvents this response by interfering with chemokine function (inhibiting the chemokines themselves, their receptors, or their signaling pathways) and bypassing NK cells. UL22A is a chemokine modulator expressed by HCMV that leads to a decline in leukocyte infiltration into the area of infection by attenuating CC chemokines and specifically inhibiting RNATES.[153,154] Additionally, the virus has the ability to impair the patrolling function of Leukocytes in the bloodstream by upregulating US28, which acts as a receptor for CX3CL1. As a further point, US28 counteracts the effects of some CC chemokines targeted by UL22.[155] Viral chemokines, like vCXCL1 (encoded by UL146), may also be produced by human CMV. These chemokines attract cells with CXCR1/2 receptors to the environment, such as neutrophils, and attach to these receptors to adapt them into carriers that help spread the virus to uninfected cells.[156,157] Additionally, vCXCL1 increases PD-L1 protein levels

in liver cells, which increases the resistance of these cells to CD8 T cell killing.[158] HCMV encodes four 7-transmembrane membrane proteins (7TM), including US28, US27, UL33 and UL78. These proteins share significant sequence homology with human chemokine receptors. The combination of two different 7TM proteins may reveal new functional properties. For example, UL33 and UL78 form heterodimers with the human chemokine receptors CCR5 and CXCR4, causing a decrease in cell surface expression, a decrease in ligand-induced internalization, disruption of signaling, and changes in the migratory functions of CCR5 and CXCR4.[159]

Natural killer (NK) cells are vital for combating HCMV as they eliminate infected cells without prior immunization.[160-162] NK cells eradicate HCMV-infected cells and induce apoptosis by releasing perforin and granzymes.[163,164] They secrete interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which enhance antiviral defense and recruit other immune cells.[165,166] NK cells recognize cells with reduced MHC class I molecules, a common strategy of HCMV to evade cytotoxic T cells.[167] Certain NK cell subsets (e.g., NKG2C[+] cells) exhibit memory-like responses and improve long-term HCMV control.[168] The ability of HCMV to evade NK cell-mediated immunity is crucial to its survival and pathogenesis. The human CMV virus resorts to multiple strategies to evade NK cells. The most important include missing-self-recognition evasion, in which cells downregulate MHC-I molecules, and induced-self recognition evasion, in which cells express ligands that increase NK cell activation, IgG targeting, and Fc receptor inhibition, which leads to blocking of the antibody-dependent cellular cytotoxicity (ADCC) process in NK cells and targets adhesion molecules and, or other molecules involved in NK functions. These strategies lead to the disarmament of NK cells, thereby impairing their executive functions. HCMV can evade missing-self recognition by upregulating 2 factors, UL18 and UL40. By forming a complex with beta-2 microglobulin (β2M), the UL18 factor functions as an MHC-I homologue, reducing the cytotoxicity of LIR1[+] NK cells through high-affinity binding to the inhibitory receptor LIR1.[169-171] Furthermore, the peptides encoded by UL40 mimic the signal peptide sequence of the MHC molecule, which, by binding to HLA-E, increases the expression of this NK cell inhibitory ligand on the infected cell surface.[172-175]

Stressed cells such as HCMV-infected cells express ligands for NK-activating receptors (such as NKG2D, 2B4, and NCRs), which promote induced-self recognition. By expressing factors such as UL142, UL148A, US9, US18, and US20, HCMV targets the NKG2D ligand called MIC-A and causes lysosomal degradation or retention in the Golgi network.[131,176-178] Another NKG2D ligand, MIC-B, is targeted by the UL16 and miR-UL112 factors expressed by HCMV.[179-183] Combined, UL16 is empowered to target other NK cell-activating ligands such as ULBP1, ULBP2, and ULBP6.[184,185] UL142 is an MHC-like factor that maintains MICA and ULBP3 in the cell and prevents their access to NK-activating receptors.[179] Natural cytotoxicity receptors (NCRs) are a family of activating receptors expressed on natural killer (NK) cells and include NKp30, NKp44, and NKp46. They play an important role in activating NK cells and the subsequent elimination of target cells. The pp65 factor expressed by HCMV can directly target NKp30.[186] In addition, the expression of the NKp30 ligand (B7-H6) on the surface of infected cells is reduced by the factors US18 and US20.[131,187]

NK cells have the potential to bind to virus-infected and IgG-coated cells via the FcγRIIIa receptor (CD16a), leading to antibody-dependent cellular cytotoxicity (ADCC). However, HCMV leads to reinfection in the presence of different types of protective IgG, suggesting that HCMV can effectively neutralize the functions of antibodies. HCMV has the RL11 gene cluster, which encodes factors such as gp34, gpRL13, and gp95, and the gene region between UL118-UL119, which encodes the gp68 factor. The factors gp68 and gp34, which can bind to the Fc of all IgG isotypes, place their Fc region beyond the reach of CD16, leading to ADCC inhibition. The factors gp35 and gpRL13 are specific only for IgG1,2 and remove it from the reach of NK cells through the internalization of antibodies.[188-192] CMV can target ligands and adhesion molecules of NK cells through the upregulation of distinct factors. CMV expresses other factors such as US2, UL11, and UL141, each of which leads to evasion of NK responses through different mechanisms. US2 activity affects NK functions, such as suppression of integrin signaling and suppression of cell adhesion and migration.[193] The CMV UL141 glycoprotein, despite its lack of homology to TNF family cytokines, can bind to the ectodomains of TRAIL-DRs, leading to its retention in the cell, thereby

protecting the infected cell from TRAIL-dependent NK cell-mediated killing.[194]

Modulation of Acquired Immune Responses

The acquired immune response plays an important role in the control of HCMV infection. The acquired immune response, particularly CD8[+] T cells, is crucial for controlling primary HCMV infection. These T cells target the infected cells and prevent the virus from replicating and disseminating.[125,195-198] After primary infection, HCMV develops a latent state in certain cell types.[199] The acquired immune response helps maintain this latency by controlling the virus.[200] In immunocompromised individuals or during phases of immunosuppression, HCMV can reactivate from latency.[201] The adaptive immune response, particularly memory T cells, is crucial in preventing or limiting such reactivation. The acquired immune response provides long-lasting immunity against HCMV but does not eliminate the virus.[202,203] This immunity helps prevent reinfection and serious illness in most people.[203] However, HCMV has evolved mechanisms to evade the acquired immune response. HCMV can reduce the expression of MHC class I molecules on infected cells, reducing the likelihood that they will be recognized by CD8[+] T cells.[204,205] HCMV can also affect various functional aspects of the acquired immune response.[85,203]

HCMV can reduce antigen presentation to T lymphocytes through various strategies, such as reducing the expression of MHC molecules or interfering with peptide loading mechanisms on MHC molecules.[206,207] The products of the US6 gene family (including US2, US3, US6, and US11), as well as the tegument factors pp65 and pp71, have the potential to reduce MHC-I expression in myeloid dendritic cells and Langerhans cells.[208-213] The US2 and US11 subgroups target allomorphic HLA-I molecules.[214] The cytoplasmic tail of the US2 in interaction with the Sec61 complex leads to the translocation of the HLA-I heavy chain from the endoplasmic reticulum and its proteasomal degradation in the cytosol.[215] US11 interacts with HLA-I using the Derlin1 factor and a glutamine residue in its transmembrane domain, leading to its transfer to the cytosol.[216,217] HCMV also has a US10 gene that targets the HLA-G molecule through an unknown mechanism and can sometimes delay the maturation of HLA-I in infected cells.[218,219] The HCMV pp65 protein downregulates HLA-DR molecules by

mediating the accumulation of HLA-II class molecules in lysosomes, leading to degradation of the HLA-DR α chain.[220] Expression of the UL82 gene leads to the production of a factor called pp71, which plays a role in protein trafficking within the cell. Studies have shown that this factor plays an important role in limiting the transfer of HLA-I to the cell surface and its accumulation within the cell.[221] HCMV can also interfere with peptide loading through the expression of factors US3 and glycoprotein US6, leading to a reduction in its expression since MHC is not very stable without peptides. In the endoplasmic reticulum, the US3 factor inhibits its function by binding to tapasin, and HLA-I remains in the endoplasmic reticulum. The glycoprotein US6 prevents peptides produced by the proteasome from entering the endoplasmic reticulum by inhibiting TAP1/2. The UL111A gene encodes CMV-encoded human interleukin 10 (cmvIL-10), which potentiates its immunosuppressive effects by upregulating hIL-10 and directly modulating the function of acquired immune cells.[222] pUL11 can bind to CD45 on the surface of T cells and differentiate them into an anti-inflammatory phenotype that produces IL-10.[223]

Immune Response to HCMV Evasion

Viruses have evolved to mimic host molecules and bind effectively to inhibitory receptors, subverting the immune response.[224] To counteract this, the host has evolved activating receptors that specifically recognize viral proteins.[224] These activated receptors often lack inhibitory signaling motifs, allowing them to trigger an immune response without viral interference. Evolution has favored a relatively simple solution to this complex problem: modification of existing inhibitory receptors.[225-227] By removing inhibitory signaling motifs and adding a charged amino acid, the host can convert these receptors into potent activating receptors.[228] This strategy proved effective and efficient across various species that independently adopted it.[229]

HCMV has developed mechanisms to evade immune detection, including expression of the UL40 protein. UL40 interacts with HLA-E and alters its distribution at the cell surface. This manipulation could prevent NK cells from recognizing infected cells.[230,231] However, NK cells expanded with the CD94-NKG2C receptor can recognize these altered HLA-E complexes thanks to their specific sensitivity to UL40-induced changes. The proliferation and differentiation of these specialized NK

cells is significantly influenced by the inflammatory environment. An inflammatory milieu, possibly created by the viral infection itself, provides the necessary signals for the proliferation and maturation of these cells. The CD94⁻NKG2C receptors on these NK cells are remarkably sensitive to even minor changes in the HLA-E binding sequence. This novel sensitivity allows them to detect subtle changes caused by the UL40 protein and identify infected cells.[232,233] No identified immunoevasins to date have been reported to target killer cell-like immunoglobulin-like receptors (KIRs), which constitute a major class of MHC-I-binding receptors in humans. The lack of KIR-targeting immunoevasins may be an evolutionary blind spot for CMV.[234] Understanding the role of KIR in viral infections can lead to developing new therapeutic strategies. Epidemiological studies have linked specific KIR alleles to the outcome of various viral infections, including CMV, hepatitis C, and HIV.[235,236] This suggests that targeting KIRs can enhance immune responses against CMV and other viral infections.

The detailed investigation of the immune evasion mechanisms of HCMV provides valuable insights that can significantly advance the development of innovative vaccines. These mechanisms, which target multiple arms of the immune system, reveal critical vulnerabilities that can be exploited for therapeutic interventions. The viral proteins such as UL18, UL40, and RL11 family members, which mimic or disrupt host immune functions, could be integrated as targets in subunit or peptide-based vaccination strategies. By developing immunogens that elicit robust responses specifically against these immunoevasins, vaccines can improve immune recognition and neutralize these evasion pathways. Modulation of the innate immune system by HCMV via pathways such as NK cell inhibition (e.g., UL18 and UL40 interactions) and chemokine dysregulation provides opportunities for adjuvant design. Vaccines could contain adjuvants that mimic natural NK cell activators or restore chemokine functions to enhance early antiviral responses.[237-240] Understanding how HCMV downregulates the expression of MHC molecules via the US2 and US11 proteins provides a blueprint for vaccines aimed at restoring or bypassing these antigen presentation pathways. For example, peptide-based vaccines could use modified epitopes designed to resist degradation or improve T cell recognition. The virus' strategies to avoid antibody-mediated cytotoxicity through Fc-binding proteins (e.g., gp68, gp34) suggest that monoclonal antibodies designed to avoid these viral traps will complement vaccination efforts and provide both preventive and therapeutic benefits could offer. Adaptive development of activating receptors to combat viral mimicry, such as NK receptors sensitive to UL40-modified HLA-E, could inspire novel vaccine platforms. These could include engineered NK cells or receptor-based therapies that, in combination with vaccines, provide improved immunity. Strategies targeting viral factors that influence latency (e.g., IE1-p72) and reactivation (e.g., pp71) could be essential components of vaccine formulations to effectively control both acute and latent phases of infection. Overall, a deep understanding of HCMV's immune evasion tactics underscores the necessity of developing multi-pronged vaccines that target both innate and adaptive immune responses. Combining these insights with advanced immunological tools such as mRNA platforms and vector-based vaccines can lead to transformative breakthroughs in the prevention and control of HCMV infections.

Correlate of Protection

Correlates of protection (CoPs) are measurable immune responses or markers that are statistically associated with protection against clinical disease. These markers help identify the immune mechanisms that prevent infection or reduce disease severity, serving as critical benchmarks in vaccine development.[241] In HCMV vaccine research, CoPs are essential for identifying the immune responses needed to protect against HCMV. For instance, antibodies targeting viral glycoproteins such as gB and the PC and cellular responses involving CD8⁺ T cells are considered potential CoPs.[242] However, the lack of understanding of these markers has led to several challenges in developing effective vaccines. Despite significant progress in HCMV vaccine development, significant uncertainties remain. For example, the precise role of antibodies in innate protection against HCMV is not fully understood. There is evidence that antibodies can inhibit the growth of cells against viruses, but this role requires further study.[13,243-245] Studies suggest that antibodies and CD8⁺ cells are the most important protective factors against HCMV. Consequently, new technologies in production and excision should focus on stimulating humoral (antibodies) and cellular immune responses.[123] HCMV has glycoproteins that bind to cell

surface receptors and enter cells in a manner that depends on the type of virus entering the cell. For example, in fibroblasts, the combination of glycoproteins gH, gL, and gO binds to the PDGFRα receptor and promotes the fusion of gB with the cell membrane at neutral pH. On the other hand, in epithelial and endothelial cells, the pentameric complex (consisting of UL128, UL130, UL131A, gH, and gL) binds to neuropilin 2 and activates pH-dependent endocytosis.[246]

During vaccine development, different antigens can be targeted using multiple platforms, such as nucleotide-based platforms, to achieve the desired CoPs. Antibodies to gB neutralize infection of fibroblast cells, and gB is considered an important target for virus-neutralizing vaccines.[10,11] Antibodies against the PC inhibit infection of endothelial, epithelial, and myeloid cells and are considered key candidates for vaccine development.[13,14] Antigens such as PP65 and IE1 are effective triggers of cellular immune responses.[12,247] The main goal of developing a vaccine against HCMV should be to enhance the host's immune response and disrupt the function of the virus at various stages of infection, including acquisition, systemic replication, and pathogenesis, as well as inhibit its reactivation to reduce the burden of illness. Because the stages of HCMV infection occur at different anatomical sites, the immune properties associated with each site may be different. For example, an immune agent that facilitates viral clearance in the mucosa may not affect reducing HCMV viremia in the patient's blood, which is one of the major challenges in vaccine development. Advances in identifying CoPs and understanding their mechanisms, coupled with the development of vaccines that can fully stimulate humoral and cellular immunity, will pave the way for more effective vaccines against HCMV.[248]

Conclusions and Perspectives

The development of an effective vaccine against HCMV faces major challenges based on the complex biology of the virus, including latency, immune evasion, and the lack of a clear CoP.[249-251] However, these obstacles provide opportunities for innovative strategies that could redefine vaccine development against HCMV and other persistent viruses. The ability of the virus to establish latency represents a significant obstacle as it allows HCMV to evade immune recognition and persist in host cells indefinitely. Future vaccines could exploit insights into the molecular mechanisms of latency, such

as chromatin remodeling at the major early promoter (MIEP) and the regulatory roles of viral long non-coding RNAs and microRNAs. Vaccine formulations containing components that target these latency-maintaining pathways could activate the virus in a controlled manner and enable immune defense.[252] Alternatively, by mimicking the phenomenon of natural memory inflation, vaccines can generate long-lived tissue-resident T cells capable of effectively monitoring and controlling latent reservoirs.

The complex mechanisms of HCMV immune evasion, such as modulation of MHC expression, inhibition of NK cell responses, and impairment of antibody-mediated cytotoxicity, complicate vaccine development efforts.[253,254] These evasion strategies can be counteracted by designing vaccines that elicit robust immune responses that can neutralize immunoevasins, such as UL18 and UL40, which mimic host molecules. New vaccine platforms may also utilize adjuvants that restore chemokine function or increase NK cell activity, thereby enhancing primary antiviral responses.[255,256] Furthermore, incorporating epitopes that resist viral destruction mechanisms and enhance T cell recognition could improve vaccine efficacy. The lack of definitive CoPs for HCMV complicates vaccine development.[251] Advances in understanding immune responses to HCMV suggest that vaccines should simultaneously stimulate strong humoral and cellular immunity. Antibodies against gB and PC are effective in neutralizing HCMV infections in various cell types, making them prime candidates for inclusion in vaccine formulations.[251] Furthermore, cellular immune responses targeting antigens such as pp65 and IE1 are crucial for controlling active and latent infections,[34] Using these insights, vaccine platforms such as mRNA-based vaccines or viral vector-based vaccines could deliver a comprehensive immune response.[34]

Innovative vaccine technologies, including mRNA platforms, provide unprecedented flexibility in targeting multiple HCMV antigens. mRNA vaccines encoding gB, pp65, and PC antigens have shown promise in inducing strong humoral and cellular immunity.[257] Such platforms also enable rapid adaptation to emerging HCMV strains, increasing the long-term benefits of these vaccines.[257] As an illustration, Moderna's mRNA-1647 vaccine, developed using an mRNA-based platform and incorporating the gB, pp65, and PC antigens, has advanced successfully to Phase III clinical trials.[258] Given the complex nature of HCMV interactions with the host

immune system, future vaccine designs should adopt a multifaceted approach. For example, future vaccines should focus on viral proteins that are critical for latency and reactivation, such as IE1-p72 and pp71. These vaccines should also promote the development of hybrid T/NK cell populations that express markers such as NKG2C and CD57, known for their potent antiviral effects.[259,260] Future vaccines should preferably contain multiple antigens that trigger both humoral and cellular immune responses, ensuring protection at different anatomical sites and stages of infection.[34,257] In addition, they should use adjuvants that increase the activity of immune cells impaired by HCMV evasion mechanisms, such as NK and T cells. By turning the challenges of latency, immune evasion, and CoPs into opportunities, the development of an effective HCMV vaccine becomes a tangible goal. Integrating advanced immunological tools and novel vaccine platforms will be crucial to overcome this complexity and achieve sustainable control of HCMV infections.

STATEMENT OF ETHICS

Not applicable.

FUNDING

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

Not applicable.

DATA AVAILABILITY

All the data are available in the article.

AI ASSISTANCE DISCLOSURE

Not applicable.

REFERENCES

1. ES M. Cytomegaloviruses and their replication. Fields Virol. 1996.

2. Ghonemy TA, Farag SE, Soliman SA, El-Okely A, El-Hendy Y. Epidemiology and risk factors of chronic kidney disease in the El-Sharkia Governorate, Egypt. Saudi J Kidney Dis Transpl. 2016;27(1):111-7.

3. Pass RF. Cytomegalovirus. Fields Virol. 2001:2675-705.

4. Sester U, Gärtner BC, Wilkens H, Schwaab B, Wössner R, Kindermann I, et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant. 2005;5(6):1483-9.

5. Khoury J, Storch G, Bohl D, Schuessler R, Torrence S, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6(9):2134-43.

6. Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines. 2021;9(2):97.

7. Modlin JF, Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clini Infect Dis. 2004;39(2):233-9.

8. Riley Jr HD. History of the cytomegalovirus. South Med J. 1997;90(2):184-90.

9. Plotkin S. The history of vaccination against cytomegalovirus. Med Microbiol Immunol. 2015;204:247-54.

10. Chandramouli S, Ciferri C, Nikitin PA, Caló S, Gerrein R, Balabanis K, et al. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat Commun. 2015;6(1):8176.

11. Gomes A, Baraniak I, Lankina A, Moulder Z, Holenya P, Atkinson C, et al. The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread. Nat Commun. 2023;14(1):1041.

12. Abate DA, Watanabe S, Mocarski ES. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol. 2004;78(20):10995-1006.

13. Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S, et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Soc Exp Biol Med. 2014;111(50):17965-70.

14. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PloS one. 2013;8(3):e59863.

15. Bia FJ, Griffith BP, Tarsio M, Hsiung G. Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. J Infect Dis. 1980;142(5):732-8.

16. Harrison CJ, Britt WJ, Chapman NM, Mullican J, Tracy S. Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis. 1995;172(5):1212-20.

17. Bourne N, Schleiss MR, Bravo FJ, Bernstein DI. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. J Infect Dis. 2001;183(1):59-64.

18. Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis. 2004;189(8):1374-81.

19. Schleiss MR, Stroup G, Pogorzelski K, McGregor A. Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. Vaccine. 2006;24(37-39):6175-86.

20. Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis. 2007;195(6):789-98.

21. Elek S, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet. 1974;303(7845):1-5.

22. Just M, Buergin-Wolff A, Emoedi G, Hernandez R. Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection. 1975;3(2):111-4.

23. Neff BJ, Weibel RE, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med. 1979;160(1):32-7.

24. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Annal Int Med. 1991;114(7):525-31.

25. Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell Jr DA, Shope TC, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 1994;58(11):1176-8.

26. Gönczöl E, Berencsi K, Pincus S, Endresz V, Méric C, Paoletti E, Plotkin SA. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine. 1995;13(12):1080-5.

27. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J. 1998;17(3):200-6.

28. Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). Pediatr Infect Dis J. 1999;180(3):843-6.

29. Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. Pediatr Infect Dis J. 1999;180(5):1700-3.

30. Pass RF, Duliege A-M, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. Pediatr Infect Dis J. 1999;180(4):970-5.

31. Berencsi K, Gyulai Z, Gönczöl E, Pincus S, Cox WI, Michelson S, et al. A canarypox vector–expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. Pediatr Infect Dis J. 2001;183(8):1171-9.

32. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J. 2002;21(2):133-8.

33. Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis. 2006;193(10):1350-60.

34. John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, Ciaramella G. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018;36(12):1689-99.

35. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22(1):76-98.

36. Froberg MK. CMV escapes! Ann Clin Lab Sci. 2004;34(2):123-30.

37. Collins-McMillen D, Buehler J, Peppenelli M, Goodrum F. Molecular determinants and the regulation of human

cytomegalovirus latency and reactivation. Viruses. 2018;10(8):444.

38. Krishna BA, Miller WE, O'Connor CM. US28: HCMV's swiss army knife. Viruses. 2018;10(8):445.

39. Reddehase MJ, Lemmermann NA. Cellular reservoirs of latent cytomegaloviruses. Med Microbiol Immunol. 2019;208(3):391-403.

40. Dupont L, Reeves MB. Cytomegalovirus latency and reactivation: recent insights into an age old problem. Rev Med Virol. 2016;26(2):75-89.

41. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-73.

42. Dooley AL, O'Connor CM. Regulation of the MIE locus during HCMV latency and reactivation. Pathogens. 2020;9(11):869.

43. Reeves M, Lehner P, Sissons J, Sinclair J. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J General Virol. 2005;86(11):2949-54.

44. Reeves M, MacAry P, Lehner P, Sissons J, Sinclair J. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci U S A. 2005;102(11):4140-5.

45. Bain M, Mendelson M, Sinclair J. Ets-2 Repressor Factor (ERF) mediates repression of the human cytomegalovirus major immediate-early promoter in undifferentiated non-permissive cells. J General Virol. 2003;84(1):41-9.

46. Wright E, Bain M, Teague L, Murphy J, Sinclair J. Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells. J General Virol. 2005;86(3):535-44.

47. Sinclair J. Chromatin structure regulates human cytomegalovirus gene expression during latency, reactivation and lytic infection. Biochim Biophys Acta. 2010;1799(3-4):286-95.

48. Rauwel B, Jang SM, Cassano M, Kapopoulou A, Barde I, Trono D. Release of human cytomegalovirus from latency by a KAP1/TRIM28 phosphorylation switch. Elife. 2015;4:e06068.

49. Rossetto CC, Tarrant-Elorza M, Pari GS. Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells. PLoS Pathogens. 2013;9(5):e1003366.

50. Diggins NL, Skalsky RL, Hancock MH. Regulation of latency and reactivation by human cytomegalovirus miRNAs. Pathogens. 2021;10(2):200.

51. O'Connor CM. Cytomegalovirus (CMV) Infection and Latency. MDPI; 2021. p. 342.

52. Trgovcich J, Cebulla C, Zimmerman P, Sedmak DD. Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression. J Virol. 2006;80(2):951-63.

53. Fu Y-Z, Su S, Gao Y-Q, Wang P-P, Huang Z-F, Hu M-M, et al. Human cytomegalovirus tegument protein UL82 inhibits STING-mediated signaling to evade antiviral immunity. Cell Host Microbe. 2017;21(2):231-43.

54. Krishna BA, Poole EL, Jackson SE, Smit MJ, Wills MR, Sinclair JH. Latency-associated expression of human cytomegalovirus US28 attenuates cell signaling pathways to maintain latent infection. MBio. 2017;8(6):10.

55. Zhu D, Pan C, Sheng J, Liang H, Bian Z, Liu Y, et al. Human cytomegalovirus reprogrammes haematopoietic progenitor cells into immunosuppressive monocytes to achieve latency. Nat Microbiol. 2018;3(4):503-13.

56. Krishna BA, Humby MS, Miller WE, O'Connor CM. Human cytomegalovirus G protein-coupled receptor US28 promotes latency by attenuating c-fos. Proc Natl Acad Sci U S A. 2019;116(5):1755-64.

57. Taylor-Wiedeman J, Sissons JP, Borysiewicz LK, Sinclair J. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J General Virol. 1991;72(9):2059-64.

58. Kondo K, Xu J, Mocarski ES. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci U S A. 1996;93(20):11137-42.

59. Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J General Virol. 1996;77(12):3099-102.

60. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A. 1998;95(7):3937-42.

61. Poole E, Juss JK, Krishna B, Herre J, Chilvers ER, Sinclair J. Alveolar macrophages isolated directly from human cytomegalovirus (HCMV)–seropositive individuals are sites of HCMV reactivation in vivo. J Infect Dis. 2015;211(12):1936-42.

62. Stern L, Withers B, Avdic S, Gottlieb D, Abendroth A, Blyth E, Slobedman B. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol. 2019;10:1186.

63. Sindre H, Tjoonnfjord G, Rollag H, Ranneberg-Nilsen T, Veiby OP, Beck S, et al. Human cytomegalovirus

suppression of and latency in early hematopoietic progenitor cells. 1996.

64. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J General Virol. 2006;87(7):1763-79.

65. Doniger J, Muralidhar S, Rosenthal LJ. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin Microbiol Rev. 1999;12(3):367-82.

66. Hale AE, Collins-McMillen D, Lenarcic EM, Igarashi S, Kamil JP, Goodrum F, Moorman NJ. FOXO transcription factors activate alternative major immediate early promoters to induce human cytomegalovirus reactivation. Proc Natl Acad Sci U S A. 2020;117(31):18764-70.

67. Krishna BA, Wass AB, O'Connor CM. Activator protein-1 transactivation of the major immediate early locus is a determinant of cytomegalovirus reactivation from latency. Proc Natl Acad Sci U S A. 2020;117(34):20860-7.

68. Tang Q, Li L, Maul GG. Mouse cytomegalovirus early M112/113 proteins control the repressive effect of IE3 on the major immediate-early promoter. J Virol. 2005;79(1):257-63.

69. Collins-McMillen D, Kamil J, Moorman N, Goodrum F. Control of immediate early gene expression for human cytomegalovirus reactivation. Front Cell Infect Microbiol. 2020;10:476.

70. Heald-Sargent TA, Forte E, Liu X, Thorp EB, Abecassis MM, Zhang ZJ, Hummel MA. New insights into the molecular mechanisms and immune control of cytomegalovirus reactivation. Transplantation. 2020;104(5):e118-e24.

71. Döcke W, Fietze E, Syrbe U, von Baehr R, Volk H, Prösch S, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343(8892):268-9.

72. Kropp KA, Robertson KA, Sing G, Rodriguez-Martin S, Blanc M, Lacaze P, et al. Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state. J Virol. 2011;85(19):10286-99.

73. Reeves MB, Compton T. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase–mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J Virol. 2011;85(23):12750-8.

74. Degli-Esposti MA, Hill GR. Immune control of cytomegalovirus reactivation in stem cell transplantation. Blood. 2022;139(9):1277-88.

75. Hassan N, Eldershaw S, Stephens C, Kinsella F, Craddock C, Malladi R, et al. CMV reactivation initiates long-term expansion and differentiation of the NK cell repertoire. Front Immunol. 2022;13:935949.

76. Mihalić A, Železnjak J, Lisnić B, Jonjić S, Juranić Lisnić V, Brizić I. Immune surveillance of cytomegalovirus in tissues. Cell Mol Immunol. 2024:1-23.

77. Smith NA, Chan GC, O'Connor CM. Modulation of host cell signaling during cytomegalovirus latency and reactivation. J Virol. 2021;18:1-17.

78. Murphy JC, Fischle W, Verdin E, Sinclair JH. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J. 2002.

79. Kew VG, Yuan J, Meier J, Reeves MB. Mitogen and stress activated kinases act co-operatively with CREB during the induction of human cytomegalovirus immediate-early gene expression from latency. PLoS Pathogens. 2014;10(6):e1004195.

80. Isern E, Gustems M, Messerle M, Borst E, Ghazal P, Angulo A. The activator protein 1 binding motifs within the human cytomegalovirus major immediate-early enhancer are functionally redundant and act in a cooperative manner with the NF-κB sites during acute infection. J Virol. 2011;85(4):1732-46.

81. Chan G, Bivins-Smith ER, Smith MS, Yurochko AD. NF-κB and phosphatidylinositol 3-kinase activity mediates the HCMV-induced atypical M1/M2 polarization of monocytes. Virus Res. 2009;144(1-2):329-33.

82. Kim JH, Collins-McMillen D, Buehler JC, Goodrum FD, Yurochko AD. Human cytomegalovirus requires epidermal growth factor receptor signaling to enter and initiate the early steps in the establishment of latency in CD34+ human progenitor cells. J Virol. 2017;91(5):10.1128/jvi. 01206-16.

83. Mahmud J, Miller MJ, Altman AM, Chan GC. Human cytomegalovirus glycoprotein-initiated signaling mediates the aberrant activation of Akt. J Virol. 2020;94(16):10.1128/jvi. 00167-20.

84. Purushothaman P, Uppal T, Verma SC. Molecular biology of KSHV lytic reactivation. Viruses. 2015;7(1):116-53.

85. Le Sage V, Cinti A, Amorim R, Mouland AJ. Adapting the stress response: viral subversion of the mTOR signaling pathway. Viruses. 2016;8(6):152.

86. Altman AM, Mahmud J, Nikolovska-Coleska Z, Chan G. HCMV modulation of cellular PI3K/AKT/mTOR signaling: new opportunities for therapeutic intervention? Antiviral Res. 2019;163:82-90.

87. Chang M, Brown HJ, Collado-Hidalgo A, Arevalo JM, Galic Z, Symensma TL, et al. β-Adrenoreceptors

reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. J Virol. 2005;79(21):13538-47.

88. Vischer HF, Leurs R, Smit MJ. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol Sci. 2006;27(1):56-63.

89. Keller MJ, Wu AW, Andrews JI, McGonagill PW, Tibesar EE, Meier JL. Reversal of human cytomegalovirus major immediate-early enhancer/promoter silencing in quiescently infected cells via the cyclic AMP signaling pathway. J Virol. 2007;81(12):6669-81.

90. Bomfim GF, Priviero F, Poole E, Tostes RC, Sinclair JH, Stamou D, et al. Cytomegalovirus and Cardiovascular Disease: A Hypothetical Role for Viral G-Protein-Coupled Receptors in Hypertension. Am J Hypertension. 2023;36(9):471-80.

91. Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91(1):119-26.

92. Matalka KZ, Sidki A, Abdul-Malik SM, Thewaini A-J. Academic stress—influence on Epstein-Barr virus and cytomegalovirus reactivation, cortisol, and prolactin. Lab Med. 2000;31(3):163-8.

93. Klopack ET. Chronic Stress and Latent Virus Reactivation: Effects on Immune Aging, Chronic Disease Morbidity, and Mortality. J Gerontol. 2023;78(10):1707-16.

94. Wendland K, Thielke M, Meisel A, Mergenthaler P. Intrinsic hypoxia sensitivity of the cytomegalovirus promoter. Cell Death Dis. 2015;6(10):e1905-e.

95. Mallet C, Cochard J, Leclercq S, Trapp-Fragnet L, Chouteau P, Denesvre C. Hypoxia and HIF-1 trigger Marek's Disease Virus reactivation in lymphoma-derived latently infected T lymphocytes. J Virol. 2022;96(5):e01427-21.

96. Kowalik TF. The DNA damage response induced by infection with human cytomegalovirus and other viruses. Viruses. 2014;6(5):2155-85.

97. Wu X, Zhou X, Wang S, Mao G. DNA damage response (DDR): a link between cellular senescence and human cytomegalovirus. Virol J. 2023;20(1):250.

98. Zangger N, Oxenius A. T cell immunity to cytomegalovirus infection. Curr Opin Immunol. 2022;77:102185.

99. Larbi A, Fulop T. From "truly naïve" to "exhausted senescent" T cells: when markers predict functionality. Cytometry Part A. 2014;85(1):25-35.

100. Verma K, Ogonek J, Varanasi PR, Luther S, Bünting I, Thomay K, et al. Human CD8+ CD57-TEMRA cells: Too young to be called" old". PLoS One. 2017;12(5):e0177405.

101. Pera A, Vasudev A, Tan C, Kared H, Solana R, Larbi A. CMV induces expansion of highly polyfunctional CD4+ T cell subset coexpressing CD57 and CD154. J Leucocyte Biol. 2017;101(2):555-66.

102. Tian Y, Babor M, Lane J, Schulten V, Patil VS, Seumois G, et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat Commun. 2017;8(1):1473.

103. Zhang W, Morris AB, Peek EV, Karadkhele G, Robertson JM, Kissick HT, Larsen CP. CMV status drives distinct trajectories of CD4+ T cell differentiation. Front Immunol. 2021;12:620386.

104. Juno JA, Van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CML. Cytotoxic CD4 T cells—friend or foe during viral infection? Front Immunol. 2017;8:19.

105. Lyu M, Wang S, Gao K, Wang L, Zhu X, Liu Y, et al. Dissecting the landscape of activated CMV-stimulated CD4+ T cells in humans by linking single-cell RNA-seq with T-cell receptor sequencing. Front Immunol. 2021;12:779961.

106. Verma S, Weiskopf D, Gupta A, McDonald B, Peters B, Sette A, Benedict CA. Cytomegalovirus-specific CD4 T cells are cytolytic and mediate vaccine protection. J Virol. 2016;90(2):650-8.

107. Walton SM, Mandaric S, Torti N, Zimmermann A, Hengel H, Oxenius A. Absence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells. PLoS Pathogens. 2011;7(8):e1002214.

108. Thom JT, Weber TC, Walton SM, Torti N, Oxenius A. The salivary gland acts as a sink for tissue-resident memory CD8+ T cells, facilitating protection from local cytomegalovirus infection. Cell Rep. 2015;13(6):1125-36.

109. Brizić I, Šušak B, Arapović M, Huszthy PC, Hiršl L, Kveštak D, et al. Brain-resident memory CD8+ T cells induced by congenital CMV infection prevent brain pathology and virus reactivation. Europ J Immunol. 2018;48(6):950-64.

110. Brizić I, Hiršl L, Šustić M, Golemac M, Britt WJ, Krmpotić A, Jonjić S. CD4 T cells are required for maintenance of CD8 T RM cells and virus control in the brain of MCMV-infected newborn mice. Med Microbiol Immunol. 2019;208:487-94.

111. Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016;16(6):367-77.

112. Cicin-Sain L. Cytomegalovirus memory inflation and immune protection. Med Microbiol Immunol. 2019;208(3):339-47.

113. Munks MW, Rott K, Nesterenko PA, Smart SM, Williams V, Tatum A, et al. CD8 T Cell Memory Inflation is Driven by Latent CMV Infection of Lymphatic Endothelial Cells. bioRxiv. 2022:2022.02. 10.479848.

114. Welten SP, Yermanos A, Baumann NS, Wagen F, Oetiker N, Sandu I, et al. Tcf1+ cells are required to maintain the inflationary T cell pool upon MCMV infection. Nat Communications. 2020;11(1):2295.

115. Khan S, Zimmermann A, Basler M, Groettrup M, Hengel H. A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol. 2004;78(4):1831-42.

116. Hutchinson S, Sims S, O'Hara G, Silk J, Gileadi U, Cerundolo V, Klenerman P. A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus. PloS one. 2011;6(2):e14646.

117. Almehmadi M, Flanagan BF, Khan N, Alomar S, Christmas SE. Increased numbers and functional activity of CD 56+ T cells in healthy cytomegalovirus positive subjects. Immunology. 2014;142(2):258-68.

118. Sottile R, Panjwani MK, Lau CM, Daniyan AF, Tanaka K, Barker JN, et al. Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity. Sci Immunol. 2021;6(63):eabe6968.

119. Grutza R, Moskorz W, Senff T, Bäcker E, Lindemann M, Zimmermann A, et al. NKG2Cpos NK cells regulate the expansion of cytomegalovirus-specific CD8 T cells. J Immunol. 2020;204(11):2910-7.

120. Watzl C. Adaptive responses of innate lymphocytes. Nat Immunol. 2018;19(5):426-7.

121. Gumá M, Busch LK, Salazar-Fontana LI, Bellosillo B, Morte C, García P, López-Botet M. The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Europ J Immunol. 2005;35(7):2071-80.

122. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Exp Rev Vaccines. 2010;9(11):1303-14.

123. Anderholm K, Bierle CJ, Schleiss MR. Cytomegalovirus vaccines: current status and future prospects. Drugs. 2016;76:1625-45.

124. Gerna G, Lilleri D. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine. New Microbiol. 2019;42(1):1-20.

125. Vieira Braga FA, Hertoghs KM, van Lier RA, van Gisbergen KP. Molecular characterization of HCMV-specific immune responses: Parallels between CD8(+) T cells, CD4(+) T cells, and NK cells. Eur J Immunol. 2015;45(9):2433-45.

126. Siebels S, Czech-Sioli M, Spohn M, Schmidt C, Theiss J, Indenbirken D, et al. Merkel cell polyomavirus DNA replication induces senescence in human dermal fibroblasts in a kap1/trim28-dependent manner. Mbio. 2020;11(2):10.

127. Sayyad Z, Acharya D, Gack MU. TRIM Proteins: Key Regulators of Immunity to Herpesvirus Infection. Viruses. 2024;16(11):1738.

128. Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, et al. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A. 2003;100(24):14223-8.

129. Davison AJ, Akter P, Cunningham C, Dolan A, Addison C, Dargan DJ, et al. Homology between the human cytomegalovirus RL11 gene family and human adenovirus E3 genes. J General Virol. 2003;84(3):657-63.

130. Llano M, Gumá M, Ortega M, Angulo A, López-Botet M. Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Europ J Immunol. 2003;33(10):2744-54.

131. Fielding CA, Weekes MP, Nobre LV, Ruckova E, Wilkie GS, Paulo JA, et al. Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. Elife. 2017;6:e22206.

132. Berry R, Watson GM, Jonjic S, Degli-Esposti MA, Rossjohn J. Modulation of innate and adaptive immunity by cytomegaloviruses. Nat Rev Immunol. 2020;20(2):113-27.

133. LIR HUI. The Human Cytomegalovirus MHC Class I. J Immunol. 2007;178:4473-81.

134. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol. 1995;69(8):4830-41.

135. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL, Wiley DC. Antigen presentation subverted: structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc Natl Acad Sci U S A. 2001;98(12):6794-9.

136. Lilley BN, Ploegh HL, Tirabassi RS. Human cytomegalovirus open reading frame TRL11/IRL11

encodes an immunoglobulin G Fc-binding protein. J Virol. 2001;75(22):11218-21.

137. Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S, et al. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS pathogens. 2014;10(5):e1004058.

138. McSharry BP, Forbes SK, Cao JZ, Avdic S, Machala EA, Gottlieb DJ, et al. Human Cytomegalovirus Upregulates Expression of the Lectin Galectin 9 via Induction of Beta Interferon. J Virol. 2014;88(18):10990-4.

139. Wagenknecht N, Reuter N, Scherer M, Reichel A, Müller R, Stamminger T. Contribution of the major ND10 proteins PML, hDaxx and Sp100 to the regulation of human cytomegalovirus latency and lytic replication in the monocytic cell line THP-1. Viruses. 2015;7(6):2884-907.

140. Biolatti M, Dell'Oste V, Pautasso S, Von Einem J, Marschall M, Plachter B, et al. Regulatory interaction between the cellular restriction factor IFI16 and viral pp65 (pUL83) modulates viral gene expression and IFI16 protein stability. J Virol. 2016;90(18):8238-50.

141. Biolatti M, Dell'Oste V, Pautasso S, Gugliesi F, von Einem J, Krapp C, et al. Human cytomegalovirus tegument protein pp65 (pUL83) dampens type I interferon production by inactivating the DNA sensor cGAS without affecting STING. J Virol. 2018;92(6):10.

142. Biolatti M, Gugliesi F, Dell'Oste V, Landolfo S. Modulation of the innate immune response by human cytomegalovirus. Infect Genet Evol. 2018;64:105-14.

143. Lau J. Investigating the Role of Human Cytomegalovirus Protein LUNA in Regulating Viral Gene Expression during Latency 2019.

144. Groves IJ, Jackson SE, Poole EL, Nachshon A, Rozman B, Schwartz M, et al. Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention. Proc Natl Acad Sci U S A. 2021;118(9):e2023025118.

145. Matthews SM, Groves IJ, O'Connor CM. Chromatin control of human cytomegalovirus infection. Mbio. 2023;14(4):e00326-23.

146. Biolatti M, Dell'Oste V, Scutera S, Gugliesi F, Griffante G, De Andrea M, et al. The viral tegument protein pp65 impairs transcriptional upregulation of IL-1β by human cytomegalovirus through inhibition of NF-kB activity. Viruses. 2018;10(10):567.

147. Fu Y-Z, Su S, Zou H-M, Guo Y, Wang S-Y, Li S, et al. Human cytomegalovirus DNA polymerase subunit UL44 antagonizes antiviral immune responses by suppressing IRF3- and NF-κB-mediated transcription. J Virol. 2019;93(11):10.

148. Lau B, Kerr K, Gu Q, Nightingale K, Antrobus R, Suárez NM, et al. Human cytomegalovirus long non-coding RNA1. 2 suppresses extracellular release of the pro-inflammatory cytokine IL-6 by blocking NF-κB activation. Front Cell Infect Microbiol. 2020;10:361.

149. Feng L, Li W, Wu X, Li X, Yang X, Ran Y, et al. Human cytomegalovirus UL23 attenuates signal transducer and activator of transcription 1 phosphorylation and type i interferon response. Front Microbiol. 2021;12:692515.

150. Aoyagi M, Gaspar M, Shenk TE. Human cytomegalovirus UL69 protein facilitates translation by associating with the mRNA cap-binding complex and excluding 4EBP1. Proc Natl Acad Sci U S A. 2010;107(6):2640-5.

151. Goldmacher VS. vMIA, a viral inhibitor of apoptosis targeting mitochondria. Biochimie. 2002;84(2-3):177-85.

152. Omoto S, Guo H, Talekar GR, Roback L, Kaiser WJ, Mocarski ES. Suppression of RIP3-dependent necroptosis by human cytomegalovirus. J Biol Chemistry. 2015;290(18):11635-48.

153. Diggins NL, Hancock MH. HCMV miRNA targets reveal important cellular pathways for viral replication, latency, and reactivation. Non-coding RNA. 2018;4(4):29.

154. Wang D, Bresnahan W, Shenk T. Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc Natl Acad Sci U S A. 2004;101(47):16642-7.

155. Vomaske J, Nelson JA, Streblow DN. Human Cytomegalovirus US28: a functionally selective chemokine binding receptor. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders). 2009;9(5):548-56.

156. Lüttichau HR. The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist. J Biol Chemistry. 2010;285(12):9137-46.

157. Berg C, Wedemeyer MJ, Melynis M, Schlimgen RR, Hansen LH, Våbenø J, et al. The non-ELR CXC chemokine encoded by human cytomegalovirus UL146 genotype 5 contains a C-terminal β-hairpin and induces neutrophil migration as a selective CXCR2 agonist. PLoS Pathogens. 2022;18(3):e1010355.

158. Hu L, Wen Z, Chen J, Chen Y, Jin L, Shi H, et al. The cytomegalovirus UL146 gene product vCXCL1 promotes the resistance of hepatic cells to CD8+ T cells through up-regulation of PD-L1. Biochem Biophysical Res Communications. 2020;532(3):393-9.

159. Tadagaki K, Tudor D, Gbahou F, Tschische P, Waldhoer M, Bomsel M, et al. Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and

CXCR4 impairing their HIV coreceptor activity. Blood. 2012;119(21):4908-18.

160. Della Chiesa M, Falco M, Muccio L, Bertaina A, Locatelli F, Moretta A. Impact of HCMV infection on NK cell development and function after HSCT. Front Immunol. 2013;4:458.

161. Rölle A, Brodin P. Immune adaptation to environmental influence: the case of NK cells and HCMV. Trends Immunol. 2016;37(3):233-43.

162. Patel M, Vlahava V-M, Forbes SK, Fielding CA, Stanton RJ, Wang EC. HCMV-encoded NK modulators: lessons from in vitro and in vivo genetic variation. Front Immunol. 2018;9:2214.

163. Cederarv M, Söderberg-Nauclér C, Odeberg J. HCMV infection of PDCs deviates the NK cell response into cytokine-producing cells unable to perform cytotoxicity. Immunobiology. 2009;214(5):331-41.

164. Vieira Braga FA, Hertoghs KM, van Lier RA, van Gisbergen KP. Molecular characterization of HCMV-specific immune responses: Parallels between CD8+ T cells, CD4+ T cells, and NK cells. Europ J Immunol. 2015;45(9):2433-45.

165. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol. 2008;41(3):206-12.

166. Goldberger T, Mandelboim O, editors. The use of microRNA by human viruses: lessons from NK cells and HCMV infection. Seminars Immunopathol. 2014: Springer.

167. Halenius A, Gerke C, Hengel H. Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver? Cell Mol Immunol. 2015;12(2):139-53.

168. Bozzano F, Della Chiesa M, Pelosi A, Antonini F, Ascierto ML, Del Zotto G, et al. HCMV-controlling NKG2C+ NK cells originate from novel circulating inflammatory precursors. J Allergy Clin Immunol. 2021;147(6):2343-57.

169. Park B, Oh H, Lee S, Song Y, Shin J, Sung YC, et al. The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US) 2, US3, US6, and US11 gene products. J Immunol. 2002;168(7):3464-9.

170. Kim Y, Park B, Cho S, Shin J, Cho K, Jun Y, Ahn K. Human cytomegalovirus UL18 utilizes US6 for evading the NK and T-cell responses. PLoS Pathogens. 2008;4(8):e1000123.

171. Yang Z, Bjorkman PJ. Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc Natl Acad Sci U S A. 2008;105(29):10095-100.

172. Kleijnen MF, Huppa JB, Lucin P, Mukherjee S, Farrell H, Campbell AE, et al. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 1997.

173. Hoare HL, Sullivan LC, Pietra G, Clements CS, Lee EJ, Ely LK, et al. Structural basis for a major histocompatibility complex class Ib–restricted T cell response. Nat Immunol. 2006;7(3):256-64.

174. Corbett AJ, Forbes CA, Moro D, Scalzo AA. Extensive sequence variation exists among isolates of murine cytomegalovirus within members of the m02 family of genes. J General Virol. 2007;88(3):758-69.

175. Sullivan LC, Walpole NG, Farenc C, Pietra G, Sum MJ, Clements CS, et al. A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors. J Biol Chemistry. 2017;292(51):21149-58.

176. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, et al. Host immune system gene targeting by a viral miRNA. Science. 2007;317(5836):376-81.

177. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annual Rev Immunol. 2013;31(1):413-41.

178. Charpak-Amikam Y, Kubsch T, Seidel E, Oiknine-Djian E, Cavaletto N, Yamin R, et al. Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20. Sci Rep. 2017;7(1):8661.

179. Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar P, Johnson DC, Cosman D. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med. 2003;197(11):1427-39.

180. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier LL. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med. 2003;197(10):1245-53.

181. Smith L, McWhorter A, Masters L, Shellam G, Redwood A. Laboratory strains of murine cytomegalovirus are

genetically similar to but phenotypically distinct from wild strains of virus. J Virol. 2008;82(13):6689-96.

182. Arapovic J, Lenac T, Antulov R, Polic B, Ruzsics Z, Carayannopoulos LN, et al. Differential susceptibility of RAE-1 isoforms to mouse cytomegalovirus. J Virol. 2009;83(16):8198-207.

183. Martins JP, Andoniou CE, Fleming P, Kuns RD, Schuster IS, Voigt V, et al. Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. Science. 2019;363(6424):288-93.

184. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, et al. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol. 2001;31(5):1428-37.

185. Patel M, Vlahava VM, Forbes SK, Fielding CA, Stanton RJ, Wang ECY. HCMV-Encoded NK Modulators: Lessons From in vitro and in vivo Genetic Variation. Front Immunol. 2018;9:2214.

186. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol. 2005;6(5):515-23.

187. Charpak-Amikam Y, Kubsch T, Seidel E, Oiknine-Djian E, Cavaletto N, Yamin R, et al. Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20. Sci Rep. 2017;7(1):8661.

188. Lilley BN, Ploegh HL, Tirabassi RS. Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein. J Virol. 2001;75(22):11218-21.

189. Atalay R, Zimmermann A, Wagner M, Borst E, Benz C, Messerle M, Hengel H. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol. 2002;76(17):8596-608.

190. Sprague ER, Reinhard H, Cheung EJ, Farley AH, Trujillo RD, Hengel H, Bjorkman PJ. The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol. 2008;82(7):3490-9.

191. Cortese M, Calò S, D'Aurizio R, Lilja A, Pacchiani N, Merola M. Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc. PLoS One. 2012;7(11):e50166.

192. Ndjamen B, Joshi DS, Fraser SE, Bjorkman PJ. Characterization of Antibody Bipolar Bridging Mediated by the Human Cytomegalovirus Fc Receptor gp68. J Virol. 2016;90(6):3262-7.

193. Hsu JL, van den Boomen DJ, Tomasec P, Weekes MP, Antrobus R, Stanton RJ, et al. Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141. PLoS Pathog. 2015;11(4):e1004811.

194. Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemčovičová I, Wang EC, et al. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe. 2013;13(3):324-35.

195. Gabanti E, Bruno F, Lilleri D, Fornara C, Zelini P, Cane I, et al. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both r equired for prevention of HCMV disease in seropositive solid-organ tra nsplant recipients. PloS one. 2014;9(8):e106044.

196. Marchant A, Appay V, Van Der Sande M, Dulphy N, Liesnard C, Kidd M, et al. Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest. 2003;111(11):1747-55.

197. Hertoghs KM, Moerland PD, van Stijn A, Remmerswaal EB, Yong SL, van de Berg PJ, et al. Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J Clin Invest. 2010;120(11):4077-90.

198. Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 2003;77(9):5226-40.

199. Wills MR, Poole E, Lau B, Krishna B, Sinclair JH. The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies? Cell Mol Immunol. 2015;12(2):128-38.

200. Elder E, Sinclair J. HCMV latency: what regulates the regulators? Med Microbiol Immunol. 2019;208(3-4):431-8.

201. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-73.

202. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673-85.

203. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res. 2011;157(2):151-60.

204. Warren AP, Ducroq D, Lehner PJ, Borysiewicz LK. Human cytomegalovirus-infected cells have unstable

assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol. 1994;68:2822 - 9.

205. Manandhar T, Hò G-GT, Pump WC, Blasczyk R, Bade-Doeding C. Battle between Host Immune Cellular Responses and HCMV Immune Evasion. Int J Mol Sci. 2019;20.

206. Hengel H, Flohr T, Hämmerling GnJ, Koszinowski UH, Momburg F. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J General Virol. 1996;77 (Pt 9):2287-96.

207. Cebulla CM, Miller DM, Zhang Y, Rahill BM, Zimmerman PD, Robinson JM, Sedmak DD. Human Cytomegalovirus Disrupts Constitutive MHC Class II Expression1. J Immunol. 2002;169:167 - 76.

208. Park B, Oh H, Lee S, Song YJ, Shin J, Sung YC, et al. The MHC Class I Homolog of Human Cytomegalovirus Is Resistant to Down-Regulation Mediated by the Unique Short Region Protein (US)2, US3, US6, and US11 Gene Products1. J Immunol. 2002;168:3464 - 9.

209. Rehm A, Engelsberg A, Tortorella D, Körner IJ, Lehmann I, Ploegh HL, Höpken UE. Human Cytomegalovirus Gene Products US2 and US11 Differ in Their Ability To Attack Major Histocompatibility Class I Heavy Chains in Dendritic Cells. J Virol. 2002;76:5043 - 50.

210. Schempp S, Topp MS, Kessler T, Sampaio KL, Dennehy KM, Einsele H, et al. Deletion mutant of human cytomegalovirus lacking US2-US6 and US11 maintains MHC class I expression and antigen presentation by infected dendritic cells. Virus Res. 2011;155 2:446-54.

211. Trgovcich J, Cebulla CM, Zimmerman PD, Sedmak DD. Human Cytomegalovirus Protein pp71 Disrupts Major Histocompatibility Complex Class I Cell Surface Expression. J Virol. 2006;80:951 - 63.

212. Hesse J, Reyda S, Tenzer S, Besold K, Reuter N, Krauter S, et al. Human Cytomegalovirus pp71 Stimulates Major Histocompatibility Complex Class I Presentation of IE1-Derived Peptides at Immediate Early Times of Infection. J Virol. 2013;87:5229 - 38.

213. Nikmanesh Y, Karimi MH, Yaghobi R, Marashi SM, Mahmoudi M, Moravej A, Shahmahmoodi S. Improved Function and Maturation of Dendritic Cells Stimulated by Recombinant pp65 Protein: An in-vitro Design. Iranian J Immunol. 2019;16 1:11-25.

214. van der Wal FJ, Kikkert M, Wiertz E. The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol. Curr Top Microbiol Immunol. 2002;269:37-55.

215. Orešić K, Noriega VM, Andrews L, Tortorella D. A Structural Determinant of Human Cytomegalovirus US2 Dictates the Down-regulation of Class I Major Histocompatibility Molecules*. J Biol Chemistry. 2006;281:19395 - 406.

216. Jun Y, Cho S, Lee M. Cytosolic interaction between MHC-I molecules and Derlin-1 is required for human cytomegalovirus US11-induced degradation of MHC-I molecules (P6122). J Immunol. 2013.

217. Cho S, Lee M, Jun Y. Forced interaction of cell surface proteins with Derlin-1 in the endoplasmic reticulum is sufficient to induce their dislocation into the cytosol for degradation. Biochem Biophys Res Commun. 2013;430 2:787-92.

218. Furman MH, Dey N, Tortorella D, Ploegh HL. The Human Cytomegalovirus US10 Gene Product Delays Trafficking of Major Histocompatibility Complex Class I Molecules. J Virol. 2002;76:11753 - 6.

219. Park B, Spooner E, Houser B, Strominger JL, Ploegh HL. The HCMV membrane glycoprotein US10 selectively targets HLA-G for degradation. J Exp Med. 2010;207:2033 - 41.

220. Odeberg J, Plachter B, Brandén L, Söderberg-Nauclér C. Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain. Blood. 2003;101(12):4870-7.

221. Trgovcich J, Cebulla C, Zimmerman P, Sedmak DD. Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression. J Virol. 2006;80(2):951-63.

222. Avdic S, McSharry BP, Steain M, Poole E, Sinclair J, Abendroth A, Slobedman B. Human Cytomegalovirus-Encoded Human Interleukin-10 (IL-10) Homolog Amplifies Its Immunomodulatory Potential by Upregulating Human IL-10 in Monocytes. J Virol. 2016;90(8):3819-27.

223. Zischke J, Mamareli P, Pokoyski C, Gabaev I, Buyny S, Jacobs R, et al. The human cytomegalovirus glycoprotein pUL11 acts via CD45 to induce T cell IL-10 secretion. PLoS Pathog. 2017;13(6):e1006454.

224. Ong EZ, Chan KR, Ooi EE. Viral Manipulation of Host Inhibitory Receptor Signaling for Immune Evasion. PLoS Pathogens. 2016;12.

225. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors. Science. 2002;296:1323 - 6.

226. Biassoni R, Ugolotti E, De Maria A. Comparative analysis of NK-cell receptor expression and function

across primate species: Perspective on antiviral defenses. Self/nonself. 2010;1 2:103-13.

227. Carrillo-Bustamante P, Keşmir C, de Boer RJ. The evolution of natural killer cell receptors. Immunogenetics. 2015;68:3 - 18.

228. Blokhuis JH, Doxiadis GGM, Bontrop R. A splice site mutation converts an inhibitory killer cell Ig-like receptor into an activating one. Mol Immunol. 2009;46 4:640-8.

229. Taylor LS, Paul S, McVicar DW. Paired inhibitory and activating receptor signals. Rev Immunogenetics. 2000;2 2:204-19.

230. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, Weiss EH. Cutting Edge: The Human Cytomegalovirus UL40 Gene Product Contains a Ligand for HLA-E and Prevents NK Cell-Mediated Lysis1. J Immunol. 2000;164:5019 - 22.

231. Braud VM, Tomasec P, Wilkinson GWG. Viral evasion of natural killer cells during human cytomegalovirus infection. Curr Top Microbiol Immunol. 2002;269:117-29.

232. López-Botet M, Muntasell A, Vilches C. The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection. Seminars Immunol. 2014;26 2:145-51.

233. Guma M, Budt M, Sáez A, Brckalo T, Hengel H, Angulo A, López-Botet M. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood. 2006;107 9:3624-31.

234. López-Botet M, Angulo A, Gumá M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens. 2004;63 3:195-203.

235. Bashirova AA, Thomas R, Carrington MN. HLA/KIR restraint of HIV: surviving the fittest. Annual Rev Immunol. 2011;29:295-317.

236. Jamil KM, Khakoo SI. KIR/HLA Interactions and Pathogen Immunity. J Biomed Biotechnol. 2011;2011.

237. Aicheler RJ, Wang EC, Tomasec P, Wilkinson GW, Stanton RJ. Potential for natural killer cell-mediated antibody-dependent cellular cytotoxicity for control of human cytomegalovirus. Antibodies. 2013;2(4):617-35.

238. Goodier MR, Jonjić S, Riley EM, Juranić Lisnić V. CMV and natural killer cells: shaping the response to vaccination. Europ J Immunol. 2018;48(1):50-65.

239. Wagstaffe HR, Mooney JP, Riley EM, Goodier MR. Vaccinating for natural killer cell effector functions. Clin TransImmunol. 2018;7(1):e1010.

240. Forrest C, Gomes A, Reeves M, Male V. NK cell memory to cytomegalovirus: implications for vaccine development. Vaccines. 2020;8(3):394.

241. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(11):1615-7.

242. Schleiss MR. Does public perception of exposure risks and transmission mechanisms drive antiviral vaccine awareness? What if cytomegalovirus was transmitted by mosquitoes? Curr Opin Virol. 2016;17:126-9.

243. Cui X, Lee R, Adler SP, McVoy MA. Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. J Virol methods. 2013;192(1-2):44-50.

244. Jacob CL, Lamorte L, Sepulveda E, Lorenz IC, Gauthier A, Franti M. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. Virology. 2013;444(1-2):140-7.

245. Chiuppesi F, Wussow F, Johnson E, Bian C, Zhuo M, Rajakumar A, et al. Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH/gL pentamer potently block primary cytotrophoblast infection. J Virol. 2015;89(23):11884-98.

246. Vanarsdall AL, Johnson DC. Human cytomegalovirus entry into cells. Current opinion in virology. 2012;2(1).

247. Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, Stroncek DF. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Trans Med. 2007;5:1-16.

248. Nelson CS, Baraniak I, Lilleri D, Reeves MB, Griffiths PD, Permar SR. Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease. J Infect Dis. 2020;221(Suppl 1):S45-s59.

249. Schleiss MR. Cytomegalovirus vaccine development. Current topics in microbiology and immunology. 2008;325:361-82.

250. Inoue N, Abe M, Kobayashi R, Yamada S. Vaccine Development for Cytomegalovirus. Advances in experimental medicine and biology. 2018;1045:271-96.

251. Gerna G, Lilleri D. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine. The new microbiologica. 2019;42 1:1-20.

252. Rouse BT, Schmid DS. Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy. Viruses. 2022;14(5).

253. Xia L, Su R, An Z, Fu TM, Luo W. Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy. Hum Vaccin Immunother. 2018;14(2):292-303.

254. Goodier MR, Jonjić S, Riley EM, Juranić Lisnić V. CMV and natural killer cells: shaping the response to vaccination. Eur J Immunol. 2018;48(1):50-65.

255. Mohan T, Zhu W, Wang Y, Wang BZ. Applications of chemokines as adjuvants for vaccine immunotherapy. Immunobiology. 2018;223(6-7):477-85.

256. Wagstaffe HR, Mooney JP, Riley EM, Goodier MR. Vaccinating for natural killer cell effector functions. Clin Transl Immunology. 2018;7(1):e1010.

257. Hu X, Karthigeyan KP, Herbek S, Valencia SM, Jenks JA, Webster H, et al. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine. J Infect Dis. 2024;230(2):455-66.

258. ModernaTX I. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age clinicaltrials.gov2021-10-26 [updated 2024-04-24.

259. Lopez-Vergès S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011;108(36):14725-32.

260. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012;119(11):2665-74.